HomeAI · summaries
Storia in 6 fonti
Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote - Replimune Group (NASDAQ:REPL)
FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decision despite earlier staff criticism.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
FDA staff say Replimune's pivotal melanoma trial failed to prove RP1 works, pushing down stock
FDA staff criticized Replimune's RP1 melanoma drug ahead of an advisory meeting, saying its Phase 2 trial failed to prove efficacy. Shares fell 30%.
- ·
benzinga.com
Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff - Replimune Group (NASDAQ:REPL)
Replimune shares fall after FDA briefing documents questioned RP1 trial data for advanced melanoma ahead of a key advisory committee meeting.
